 MINNEAPOLIS, June 18, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, announced that it has completed the closing of its previously announced registered direct offering of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of 1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of 1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three 3 years following the date the warrants first become exercisable. 